I've never been one to mess with customer support when I can go straight to the top teehee, I'm sure you find that hard to believe....
I wrote to sanofi aventis, the pharm company that makes taxotere to ask about the alcohol content and alcohol reactions/side effects. A rep called me yesterday-missed call due to east/west time change. He called back this morning (which impressed me). Of course, the alcohol content issue has never been studied.
I also asked if anything new was in the pipeline...he referred me to clinicaltrials.gov (which is an interesting website, btw). Then he called back and told me about BSI-201, for triple neg bc, that trials have been looking really good. I just googled BSI-201 and found more information on it. It seems to have passed quickly thru phase II and is now in phase III, as of 7/17/09. Might be worth mentioning to your onco. While it would not help my type of bc mets, I know there are quite a few of you out there. Sounded encouraging to me so thought I would share.
Already a member? Sign in
Welcome to Inspire!
What - Inspire is a place where you can connect with people who share your health concerns and find information and advice in groups sponsored by organizations you know and trust.
Why - As a member you can use Inspire to let friends and family know how you're doing, contact others who share your health concerns, receive personalized updates and information about participating in surveys and clinical trials, and more.
How - Joining Inspire is completely free and usually takes less than a minute. Join now!
Triple Neg Breast cancer
- By maryk58
- Posted September 30, 2009 at 1:24 pm · 11 replies
- In Research findings
- Shared with the public
Explore topics in this discussion:
11 replies
- Oldest first
- Newest first
- By Saraj
- Posted September 30, 2009 at 7:26 pm
- Report post
BSI-201 is a PARP inhibitor. Yesterday I posted regarding a Phase III Clinical study due to open with a PARP Inhibitor. I had earlier posted regarding Dr. Patricia Steeg, Chief of Women's Cancer Section of the Laboratory of Molecular Pharmacology at NCI, Dr. Steeg is very enthusiastic about the future of PARP Inhibitors, especially for BRCA I and BRCA2 mutations and triple negative breast cancer. If anyone is interested, they can probably find this discussion thread.
- By sr2603
- Posted October 1, 2009 at 8:00 am
- Report post
My oncologist is trying to get me into trial with the PARP inhibitors. He seems to be very keen on trying it, so am I. Hopefully because it is moving so quickly, it will be availabe for me in the near future.
- By Analemma
- Posted October 1, 2009 at 9:13 am
- Report post
This is what everybody is talking about! I tried to get into Phase II two years ago, and it was just too inconvenient, and now Phase three won't accept me because my mets are too extensive. BS201 is not the only PARP trial going on right now, though. If you go clinicaltrials.gov and search for PARP inhibitors, you'll turn up several. I sure hope it holds promise for non-BRCA women like me.
- By EileenV
- Posted October 1, 2009 at 9:43 am
- Report post
We have the PARP clinical trial open here at our cancer center. It uses Gemcitabine with Carboplatin along with the study drug BSI which is the PARP inhibitor. The title of the study is BiPar 20090301 and the call center number for information is 1 866 668-2232 or you can go to www.clinicaltrials.gov. We are seeing excellent results so far.
Blessings to you all
Eileen
- By freedom
- Posted October 1, 2009 at 11:23 am
- Report post
I am BRCA1 positive and have triple negative disease. I currently have mets to the pleural lining of my left lung. I tried to get into a clinical trial using the PARP1 inhibitors but was disqualified because I have received carboplatin in the past. Has anyone else been disqualified for this or a similar reason?
- By Analemma
- Posted October 1, 2009 at 1:18 pm
- Report post
Yes, I had carboplatin last year when I first had mets. When we found the study was close this year (in Pittsburgh) I was excited and tried to get in, but couldn't because of previous carboplatin. As it turned out, a week or so later I got dx with another brain mets, which further disqualified me.
They are having good results, it seems, so maybe they will rush it through,, like they did herceptin. I have pleural mets, too, by the way.
- By cb224
- Posted November 18, 2009 at 4:40 am
- Report post
Does anyone have any information about whether parp inhibitor treatment is somehow more available to patients in the UK versus the US? I've searched clinicaltrials.gov and some UK trials appear along with the US-based ones, but I had separately heard that the availability of parp inhibitors was greater in the UK.
My question specifically relates to a scenario where a US resident travels to the UK for treatment. Is it "easier" for a US resident to get parp inhibitor treatment in the UK versus in the US, where they have to qualify for a clinical trial?
Any help would be appreciated!
- By momx4TNBC
- Posted November 18, 2009 at 9:27 am
- Report post
Just got back from LBBC symposium in Phili and the speaker there, from Sloan Kettering was very encouraged by the PARP inhibitors as treatment for TNBC. I don't qualify for previous carbo use as well but she did say most of the studies now are showing that the IV form of the Parps were showing better promise than the oral forms. I asked her specifically about them being released for compassionate use and she was unaware of that being done at this time! But with them in phase III trials, if these go well, hopefully it won't be long till they will be released.... One can always hope anyway......In the meantime, she said if you are on Avastin, which I am, and you are stable or NED, she said she would NOT change over to the PARPs for now....save for later....Just thought I would pass this on. Feel free to PM me and I can look at my notes to see more details. Also LBBC will have the lecture online in a few weeks as well as several others on Advanced or Metastatic Disease. It was a great conference!!! Christi
- By momx4TNBC
- Posted November 18, 2009 at 9:27 am
- Report post
Just got back from LBBC symposium in Phili and the speaker there, from Sloan Kettering was very encouraged by the PARP inhibitors as treatment for TNBC. I don't qualify for previous carbo use as well but she did say most of the studies now are showing that the IV form of the Parps were showing better promise than the oral forms. I asked her specifically about them being released for compassionate use and she was unaware of that being done at this time! But with them in phase III trials, if these go well, hopefully it won't be long till they will be released.... One can always hope anyway......In the meantime, she said if you are on Avastin, which I am, and you are stable or NED, she said she would NOT change over to the PARPs for now....save for later....Just thought I would pass this on. Feel free to PM me and I can look at my notes to see more details. Also LBBC will have the lecture online in a few weeks as well as several others on Advanced or Metastatic Disease. It was a great conference!!! Christi
- By momx4TNBC
- Posted November 18, 2009 at 9:39 am
- Report post
Oops, the nutrition speaker was from Sloan Kettering. The TNBC speaker was a woman physician, Ramona Swaby, MD from Fox Chase Cancer Center.
Christi
- By Stubborn
- Posted November 18, 2009 at 4:52 pm
- Report post
Yes, I do not qualify because of the number of chemo regimens that I have already been through. I think they only allow 2 previous. I am currently on Gemzar and Carboplatin but have not had a scan yet to see if it is working. I contacted BiPar the drug company and the woman there said they are going to expand the trial so maybe there is hope for us.
Add to the discussion